BetterLife Pharma Seeks Shareholder Approval of Advance Notice Policy for Director Nominations

• BetterLife Pharma shareholders will vote on ratifying a director nomination advance notice policy at the December 9, 2026 shareholder meeting.
• The policy sets nomination deadlines and disclosure requirements; only candidates nominated under its provisions will be eligible for election.
• Already effective, the policy will remain in force if ratified or terminate at the meeting’s conclusion if shareholders reject it.
• Director Steven Sangha, controlling approximately 9.19% of outstanding common shares, must vote in line with management recommendations under a settlement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611060800NEWSFILECNPR____20261106_322822_1) on November 06, 2026, and is solely responsible for the information contained therein.